首页> 外文期刊>World Journal of Gastroenterology >Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
【24h】

Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.

机译:丝裂霉素联合舒林酸诱导人胃癌SGC-7901细胞凋亡。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells. METHODS: Human gastric cancer SGC-7901 cells were divided into three treatment groups,namely sulindac treatment group, MMC treatment group and combined sulindac with MMC treatment group. After being treated with drugs, cell viability was examined by MTT assay. Flow cytometry was used to evaluate the cell cycle distribution and apoptotic rates. Morphology of the cells was observed under light microscope and interactive laser microscope. Expression of COX-2 and Bcl-2 was determined by immunocytochemical method. RESULTS: After exposure for 12 h to three kinds of drugs, gastric cancer SGC-7901 cells presented some morphological features of apoptosis, including cell shrinkage, nuclear condensation, DNA fragmentation and formation of apoptotic bodies. Growth inhibition was more obvious in combined sulindac with MMC treatment group and sulindac treatment group than in MMC treatment group. The apoptotic rates in co-treated cells and MMC-treated cells 24 h after treatment were 12.0% and 7.2%, respectively. After exposure for 24 h to MMC, the expression of COX-2 and Bcl-2 protein was up-regulated, COX-2 levels were down-regulated but Bcl-2 gene expression was not changed significantly in combined treatment group. CONCLUSION: MMC-induced apoptosis is reduced by up-regulating the expression of COX-2 and Bcl-2 genes. MMC combined with sulindac can suppress the growth of gastric cancer cells through induction of apoptosis mediated by down-regulation of apoptosis-related Bcl-2 and COX-2 gene.
机译:目的:探讨丝裂霉素(MMC)联合舒林酸对胃癌SGC-7901细胞活力,凋亡诱导及凋亡相关基因Bcl-2和环氧合酶-2(COX-2)表达的影响。方法:将人胃癌SGC-7901细胞分为舒林酸治疗组,MMC治疗组和舒林酸联合MMC治疗组三个治疗组。用药物治疗后,通过MTT分析检查细胞活力。流式细胞仪用于评估细胞周期分布和凋亡率。在光学显微镜和交互式激光显微镜下观察细胞的形态。通过免疫细胞化学方法确定COX-2和Bcl-2的表达。结果:胃癌SGC-7901细胞暴露于三种药物12 h后,具有细胞凋亡的形态学特征,包括细胞萎缩,核浓缩,DNA断裂和凋亡小体的形成。舒林酸联合MMC治疗组和舒林酸治疗组的生长抑制作用比MMC治疗组更明显。处理后24小时,经共处理的细胞和经MMC处理的细胞的凋亡率分别为12.0%和7.2%。 MMC暴露24 h后,联合治疗组COX-2和Bcl-2蛋白表达上调,COX-2水平下调,但Bcl-2基因表达无明显变化。结论:通过上调COX-2和Bcl-2基因的表达来减少MMC诱导的细胞凋亡。 MMC与舒林酸联合可以通过诱导凋亡相关Bcl-2和COX-2基因下调介导的凋亡诱导胃癌细胞的生长抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号